Floatz logo

Recombinant Human Thrombopoietin

Chemotherapy-Induced Toxicity

Shandong Universityprotein_peptidePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

63 Active assets in the Chemotherapy-Induced Toxicity cohort.

Asset / SponsorPhaseRating
Palonosetron
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4A
Dexasone
Instituto do Cancer do Estado de São Paulo
Phase 4A
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Netupitant
Instituto Brasileiro de Controle do Cancer
Phase 3BB
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Human Thrombopoietin is also rated in:

thrombocytopeniaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
thrombocytopenia due to immune destructionActive
B
Indicative · Phase 3
60 / 100
View asset →
colorectal carcinomaDormant
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →